Critical Outcome Technologies Inc. - Product Pipeline Review - 2016

Published: Oct, 2016 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Critical Outcome Technologies Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Critical Outcome Technologies Inc. - Product Pipeline Review - 2016', provides an overview of the Critical Outcome Technologies Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Critical Outcome Technologies Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Critical Outcome Technologies Inc.
- The report provides overview of Critical Outcome Technologies Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Critical Outcome Technologies Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Critical Outcome Technologies Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Critical Outcome Technologies Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Critical Outcome Technologies Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Critical Outcome Technologies Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Critical Outcome Technologies Inc. Snapshot 5
Critical Outcome Technologies Inc. Overview 5
Key Facts 5
Critical Outcome Technologies Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Critical Outcome Technologies Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Critical Outcome Technologies Inc. - Pipeline Products Glance 11
Critical Outcome Technologies Inc. - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Critical Outcome Technologies Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Critical Outcome Technologies Inc. - Drug Profiles 14
COTI-2 - Drug Profile 14
Product Description 14
Mechanism Of Action 14
R&D Progress 14
COTI-219 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
COTI-4 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
COTI-58 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Small Molecule for MRSA Infection - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Small Molecules for Acute Myelocytic Leukemia - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Small Molecules for Small Cell Lung Cancer - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Small Molecules to Antagonize VEGF-R and PDGF-R for Multiple Sclerosis - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecules to Inhibit Angiogenesis for Undisclosed Indication - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecules to Inhibit CDKs for Colorectal Cancer - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules to Inhibit Microtubulin for Colorectal Cancer - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Inhibit Thymidylate Synthase and THFR for Colorectal Cancer - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Critical Outcome Technologies Inc. - Pipeline Analysis 36
Critical Outcome Technologies Inc. - Pipeline Products by Target 36
Critical Outcome Technologies Inc. - Pipeline Products by Route of Administration 37
Critical Outcome Technologies Inc. - Pipeline Products by Molecule Type 38
Critical Outcome Technologies Inc. - Pipeline Products by Mechanism of Action 39
Critical Outcome Technologies Inc. - Dormant Projects 40
Critical Outcome Technologies Inc. - Locations And Subsidiaries 41
Head Office 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables

Critical Outcome Technologies Inc., Key Facts 5
Critical Outcome Technologies Inc. - Pipeline by Indication, 2016 8
Critical Outcome Technologies Inc. - Pipeline by Stage of Development, 2016 9
Critical Outcome Technologies Inc. - Monotherapy Products in Pipeline, 2016 10
Critical Outcome Technologies Inc. - Phase I, 2016 11
Critical Outcome Technologies Inc. - Preclinical, 2016 12
Critical Outcome Technologies Inc. - Discovery, 2016 13
Critical Outcome Technologies Inc. - Pipeline by Target, 2016 36
Critical Outcome Technologies Inc. - Pipeline by Route of Administration, 2016 37
Critical Outcome Technologies Inc. - Pipeline by Molecule Type, 2016 38
Critical Outcome Technologies Inc. - Pipeline Products by Mechanism of Action, 2016 39
Critical Outcome Technologies Inc. - Dormant Developmental Projects,2016 40